Talphera (NASDAQ:TLPH) Given New $6.00 Price Target at HC Wainwright

Talphera (NASDAQ:TLPHFree Report) had its price objective raised by HC Wainwright from $5.00 to $6.00 in a report published on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Talphera’s Q4 2023 earnings at ($0.24) EPS, FY2023 earnings at ($0.55) EPS, Q1 2024 earnings at ($0.31) EPS, Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.20) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $1.02 EPS.

Talphera Trading Down 1.0 %

Talphera stock traded down $0.01 during trading on Monday, hitting $1.03. 59,035 shares of the company were exchanged, compared to its average volume of 177,224. Talphera has a 52 week low of $0.43 and a 52 week high of $2.30.

Talphera Company Profile

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

Read More

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.